NEW YORK—Covington represented Novo Nordisk A/S in its agreement to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to $1.3 billion.
Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments.
Novo Nordisk is a global healthcare company, founded in 1923 and headquartered in Denmark whose purpose is to drive change to defeat serious chronic diseases, built upon its heritage in diabetes. It does so by pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease.
KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet medical needs.
The Covington corporate team included Peter Laveran, Allison Schiffman, Barbara Asiain, Mohamed Sidibay, and Laura Bleier. Support was also provided on China-related matters by Covington lawyers in its Intellectual Property, Regulatory, and China Practice groups based in Boston, New York, California, and Shanghai.
Back
